| Literature DB >> 24876981 |
Ana Paula Molina Vivas1, Luana Eschholz Bomfin2, Clovis Antonio Lopes Pinto3, Ulisses Ribaldo Nicolau4, Fabio Abreu Alves5.
Abstract
Neurofibromatosis type 1 (NF1) has been associated with an increased risk for development of malignancy, especially malignant peripheral nerve sheath tumors. In addition, recently, literature has demonstrated an increased risk of breast cancer in women with NF1. The present paper shows a 53-year-old woman with NF1 who presented with metaplastic breast carcinoma and developed multiple metastases, including mandible. Furthermore, we reviewed the English literature, found 63 cases showing the association between NF1 and breast cancer, and added one more case. The present study demonstrated an important association between NF1 and breast cancer. Until the present time, there has been only one case of metaplastic breast carcinoma associated with NF1. Curiously, in our case the oral metastasis corresponded to sarcomatous component of metaplastic breast carcinoma.Entities:
Year: 2014 PMID: 24876981 PMCID: PMC4021739 DOI: 10.1155/2014/719061
Source DB: PubMed Journal: Case Rep Oncol Med
Figure 1(a) Abdominal surface presenting café au lait macules and multiple cutaneous neurofibromas. (b) Upper member with cutaneous neurofibromas. (c) Intraoral view showing an extensive tumor with necrotic surface located on the left retromolar area.
Figure 2(a) Histological findings of malignant neoplasia of the oral cavity, showing atypical spindle cells with a storiform arrangement (H&E stain, ×40). (b) Areas with osteoclast-like cells (H&E stain, ×400). (c) Histological findings of metaplastic breast carcinoma with carcinoma in situ area beside the sarcomatous component (H&E, ×100). (d) Invasive ductal carcinoma (H&E, ×40). (e) Sarcomatoid pattern with hemangiopericytic area (H&E, ×40). (f) Sarcomatoid component with osteoclast-like cells (H&E, ×200).
Immunohistochemical features observed in both carcinoma and sarcomatoid components and in both breast and mandibular tumors.
| Antibody | Clone | Breast Cancer | Oral metastasis | |
|---|---|---|---|---|
| Carcinoma | Sarcomatous | |||
| ER | SP1—DAKO | − | − | − |
|
| ||||
| PR | PgR636—DAKO | − | − | − |
|
| ||||
| C-erbB-e | Polyclonal—DAKO | (1+) invasive carcinoma | − | − |
| (3+) carcinoma | (0) | (0) | ||
|
| ||||
| CK5 | XM26 (mouse)—Neomarkers | − | − | − |
|
| ||||
| CK14 | LL002 (mouse)—Thermo Scientific | + carcinoma | − | − |
|
| ||||
| CKAE1/AE3 | AE1-AE3—DAKO | + | + | + |
| 1% neoplastic cells | 1% neoplastic cells | |||
|
| ||||
| p63 | 4A4—DAKO | − | + | − |
| 10% neoplastic cells | ||||
|
| ||||
| p53 | D0-7—DAKO | + | + | + |
| 20% neoplastic cells | 40% neoplastic cells | 80% neoplastic cells | ||
|
| ||||
| Ki-67 | MIB-1—DAKO | Proliferative activity | Proliferative activity | Proliferative activity |
| 50% | 80% | 90% | ||
|
| ||||
| Vimentin | V9—DAKO | − | + | + |
|
| ||||
| SMA | 1A4—DAKO | − | + focal areas | + focal areas |
|
| ||||
| Desmin | D33—DAKO | − | − | − |
|
| ||||
| Myogenin | F5D—DAKO | − | − | − |
|
| ||||
| Myo-D1 | 5.8A—DAKO | − | − | − |
|
| ||||
| S-100 | Polyclonal—DAKO | − | + focal areas | − |
|
| ||||
| CD68 | KP1—DAKO | − | + osteoclast-like cells | + osteoclast-like cells |
ER: estrogen receptor; PR: progesterone receptor; CK: cytokeratin; SMA: smooth muscle actin.
Figure 3Immunoreactivity of metaplastic carcinoma. (a) Strong immunoreactivity for vimentin in the sarcomatous component. (b) Immunoreactivity for cytokeratin AE1/AE3 is present in few cells of the sarcomatous component. (c) Reactivity for smooth muscle actin in focal area. (d) Immunoreactivity for CD68 in osteoclast-like cells. (e) Nuclear immunoreactivity for Ki-67. (f) Expression of p53 (polymer-HRP detection system, biotin-free).
Total of patients with NF1 who developed breast carcinoma considering only English language literature.
| Authors |
| Breast cancer subtype | Age (years) | Follow-up (months) |
|---|---|---|---|---|
| Brasfield and Das Gupta [ | 5 | Breast carcinoma* | 1 patient 39, the others not informed | All dead within 60 |
|
| ||||
|
McMillan and Edwards [ | 1 | Spheroidal-cell carcinoma | 27 | Dead, 168 |
|
| ||||
|
El-Zawahry et al. [ | 2 | Lobular carcinoma | 40 | Not informed |
|
| ||||
| Zöller et al. [ | 2 | Ductal carcinoma | 38 | Dead 36 |
|
| ||||
| Nakamura et al. [ | 1 | Scirrhous carcinoma | 49 | Dead 5 |
|
| ||||
| Murayama et al. [ | 1 | Ductal carcinoma | 66 | Alive 8 |
|
| ||||
| Ceccaroni et al. [ | 2 | Breast carcinoma* | 52 | Not informed |
|
| ||||
| Satgé et al. [ | 1 | Ductal carcinoma | 23 | Alive 168 |
|
| ||||
| Güran and Safali [ | 2 | Ductal carcinoma | 23 | Not informed |
|
| ||||
|
Posada and Chakmakjian [ | 1 | Lobular carcinoma | 74 | Alive 36 |
|
| ||||
| Walker et al. [ | 5 | 4 ductal carcinoma | Mean age 46.4 | Not informed |
|
| ||||
| Natsiopoulos et al. [ | 1 | Metaplastic carcinoma | 60 | Alive 30 |
|
| ||||
| Sharif et al. [ | 14 | 11 ductal carcinoma | Mean age 43.5 | 5 died mean 66 |
|
| ||||
| Hasson et al. [ | 1 | Ductal carcinoma | 49 | Not informed |
|
| ||||
| Invernizzi et al. [ | 1 | Ductal carcinoma | 60 | Alive 36 |
|
| ||||
| Alamsamimi et al. [ | 1 | Ductal carcinoma | 51 | Alive 24 |
|
| ||||
| Hegyi et al. [ | 1 | Malignant myoepithelioma | 41 | Not informed |
|
| ||||
| Salemis et al. [ | 1 | Ductal carcinoma | 59 | Alive 20 |
|
| ||||
| Bhargava et al. [ | 1 | Ductal carcinoma | 58 | Alive 13 |
|
| ||||
| Takeuchi et al. [ | 1 | Ductal and lobular carcinoma | 69 | Alive 6 |
|
| ||||
| Zhou et al. [ | 1 | Ductal carcinoma | 48 | Alive 8 |
|
| ||||
| Madanikia et al. [ | 4 | 3 ductal carcinoma | Not informed | Not informed |
|
| ||||
| Wang et al. [ | 11 | 10 ductal carcinoma | Mean age 48.8 | Not informed |
|
| ||||
| Campos et al. [ | 2 | Breast carcinoma* | 40 | Dead |
|
| ||||
| Present case | 1 | Metaplastic carcinoma | 53 | Dead 3 |
|
| ||||
| Total |
| |||
*Subtype not informed.